Navigation Links
Lithium of No Benefit in ALS, Study Finds
Date:8/11/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 11 (HealthDay News) -- A new study appears to dash hopes that the psychiatric drug lithium can benefit patients with amyotrophic lateral sclerosis (ALS).

The investigation involving 171 people with ALS was stopped early, in November 2009, because of high dropout rates from death, side effects or because patients thought the drug was ineffective.

ALS -- sometimes called Lou Gehrig's disease after the N.Y. Yankee who died of the condition -- is a progressive nervous system disorder that causes weakness in muscles, including those controlling breathing and swallowing. Median survival is three years, and only one drug -- riluzole -- is approved for ALS treatment in the United States.

Interest in lithium, which is often used to treat bipolar disorder, increased after a small Italian study was published two years ago, suggesting a beneficial effect for ALS patients, said Dr. Adriano Chio, an associate professor of neurology at the University of Torino, Italy. In that study, lithium was thought to have prolonged survival of 16 ALS patients, Chio said.

How might lithium have helped?

"Lithium could have an effect on one of the mechanisms supposedly related to the motor neuron degeneration in ALS, the accumulation of pathological proteins in the neuron," said Chio, who led the new study, noting subsequent research has not confirmed this effect.

In the new study, published in the Aug. 17 issue of Neurology, the drop-out rate, at 68 percent, was two times higher than the drop-out rate reported by previous trials, Chio said.

All participants received lithium, but in two different doses, and the drug was not well-tolerated by either group. Patients died or lost their autonomy at the same rate in both groups.

In an editorial accompanying the study, Dr. Carmel Armon of Tufts University said one limitation of the Chio study, which Chio acknowledges, is that it didn't use a true placebo, but rather different doses. Other ongoing studies that are comparing the active drug to placebo may give the definitive answers, Armon said.

"This study [by Chio] shows there are toxic doses of lithium," said Lucie Bruijn, chief scientist for the ALS Association in Washington, D.C.

"We knew lithium has to be monitored carefully in terms of dose," Bruijn said. "What's shown here [in the new study] is a toxic level in some cases and not a strong benefit."

Even at what was termed "subtherapeutic doses," the lithium was poorly tolerated, Chio found. All 71 patients reported at least one adverse event, some as serious as heart disturbance, cerebral hemorrhage or deep vein blood clots.

Chio said two other trials are assessing the effect of lithium in ALS, but he doubts any positive effect of lithium will be shown.

In the future, Chio added, stem cell therapy may prove useful for ALS.

More information

To learn more about ALS, visit the ALS Association.

SOURCES: Adriano Chio, M.D., associate professor, neurology, First Faculty of Medicine, University of Torino, Italy; Lucie Bruijn, Ph.D., chief scientist, ALS Association, Washington, D.C.; Aug. 17, 2010, Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. No Evidence That Lithium Helps in ALS
2. 30 million women to benefit from health reform law
3. Researchers study benefits of white button mushrooms
4. Study finds patients benefit from thorough discussion of recommended operations
5. Society of Interventional Radiology advances global definition of specialty, benefits patients
6. Social Security Disability Benefits Can Be Crucial to Surviving With Spinal Cord Injury, Allsup Reports
7. Advocate Health Care Reports $462 Million in Community Benefits
8. Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities
9. Mulago Positive Women's Network Announce Their "BONO" Bracelet Fundraiser to Benefit HIV+ Women in Uganda
10. Intensively lowering glucose: Possible benefits must be weighed against risks
11. Examining risks and benefits of alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lithium of No Benefit in ALS, Study Finds
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: